// App-Quantinova.ai

P673 : DEPLETION AND RECOVERY OF NORMAL B-CELLS DURING AND AFTER TREATMENT WITH CHEMOIMMUNOTHERAPY, IBRUTINIB OR VENETOCLAX.

Researchers

Presenter

  • Andy Rawstron

Principal Investigators

  • Nichola Webster

  • Surita Dalal

  • Adrian Bloor

  • Ruth de Tute

  • Anna Hockaday

  • Sharon Jackson

  • David Cairns

  • David Allsup

  • Talha Munir

  • Peter Hillmen

Medical Centers

  • Experimental Haematology, University of Leeds, Leeds, United Kingdom

  • Haematology, Christie NHS Foundation Trust, Manchester, United Kingdom

  • HMDS,Leeds Cancer Centre,Leeds,Reino Unido

  • Haematology,Leeds Cancer Centre,Leeds,Regno Unito

  • Haematology,Hull York Medical School,Hull,Verenigd Koninkrijk

  • HMDS,Leeds Cancer Cent

  • Leeds Cancer Research UK Clinical Trials Unit,Leeds Institute of Clinical Trials Research,Leeds,Vereinigtes Königreich

  • Experimental Haematology,University of Leeds,Leeds,Royaume-uni

  • Haematology,Hull York Medical School,Hull,Regno Unito

  • Haematology, Christie NHS Foundation Trust, Manchester, United Kingdom

  • Leeds Cancer Research UK Clinical Trials Unit,Leeds Institute of Clinical Trials Research,Leeds,Vereinigtes Königreich

  • Leeds Cancer Centre, Leeds, United Kingdom

  • HMDS,Leeds Cancer Centre,Leeds,Соединённое Королевство

  • Haematology,The Christie NHS Foundation T

  • Haematology,Leeds Cancer Centre,Leeds,United Kingdom

  • Haematology, Christie NHS Foundation Trust, Manchester, United Kingdom

  • Haematology,Hull York Medical School,Hull,Regno Unito

  • HMDS,Leeds Cancer Centre,Leeds,Royaume-uni

  • Leeds Cancer Research UK Clinical Trials Unit,Leeds Institute of

  • Haematology,Hull York Medical School,Hull,United Kingdom

  • Haematology,The Christie NHS Foundation Trust,Manchester,Vereinigtes Königreich

  • Haematology,Hull York Medical School,Hull,Verenigd Koninkrijk

  • Experimental Haematology,University of Leeds,Leeds,Vereinigtes Königreich

  • HMDS,Leeds Cancer Centre,Leeds,Vereinigtes Königreich

  • Haematology,Leeds Cancer Centre,Leeds,Regno Unito

  • Experimental Haematology, University of Leeds, Leeds, United Kingdom

  • Experimental Haematology,University of Leeds,Leeds,Vereinigtes Königreich

  • HMDS,Leeds Cancer Centre,Leeds,Reino Unido

  • Haematology,Hull York Medical School,Hull,Regno Unito

  • HMDS,Leeds Cancer Centre,Leeds,Vereinigtes Königreich

  • HMDS,Leeds Cancer Centre,Leeds,Verenigd Koninkrijk

  • Experimental Haematology, University of Leeds, Leeds, United Kingdom

  • Haematology,Leeds Cancer Cen

  • HMDS,Leeds Cancer Centre,Leeds,Verenigd Koninkrijk

  • Leeds Cancer Research UK Clinical Trials Unit,Leeds Institute of Clinical Trials Research,Leeds,Vereinigtes Königreich

  • Haematology,Leeds Cancer Centre,Leeds,Royaume-uni

Locations

  • United Kingdom

  • Turkey

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Cytokeratin 20

  • Cluster of Differentiation 2AP

  • Cluster of Differentiation 19

Drug/Treatment

  • Venetoclax

  • Ibrutinib

  • TP53

Outcome

  • N/A

Study Design

  • Randomized

  • Cohort

Phase

  • III

Study Id's

  • ISRCTN01844152

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved